NCT02579473View on ClinicalTrials.gov

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Parkinson's Disease
Interventions
DRUG

SER-214

SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection

Trial Locations (4)

27710

Duke University Medical Center, Durham

30912

Georgia Regents University, Augusta

33009

MD Clinical, Hallandale

35233

University of Alabama Birmingham, Birmingham

Sponsors
All Listed Sponsors
lead

Serina Therapeutics

INDUSTRY

NCT02579473 - A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214 | Biotech Hunter | Biotech Hunter